New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
16:42 EDTVRTXVertex receives European approval for KALYDECO in eight gating mutations
Vertex Pharmaceuticals announced that the European Commission has approved KALYDECO for people with cystic fibrosis ages 6 and older who have one of eight non-G551D gating mutations in the cystic fibrosis transmembrane conductance regulator gene. KALYDECO was first approved in Europe in July 2012 for people with CF ages 6 and older who have the G551D mutation, which is the most common gating mutation. The eight additional gating mutations included in today’s approval are G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P and G1349D. In Europe, approximately 250 people ages 6 and older have one of these non-G551D gating mutations.
News For VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 10, 2015
07:45 EDTVRTXVertex initiated with a Buy at Canaccord
Target $150.
April 9, 2015
10:48 EDTVRTXDeutsche compares PTC Therapeutics to Vertex, boosts target by $40
Subscribe for More Information
07:27 EDTVRTXPTC Therapeutics price target raised to $115 from $75 at Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use